BioVie Inc. announced on July 22, 2025, the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors. These appointments are expected to bring significant strategic vision and operational expertise to the company.
Dr. Chappell brings decades of experience in clinical neuroscience and drug development, including a 25-year career at Eli Lilly & Co., where she played a central role in developing and gaining FDA approvals for multiple central nervous system indications. Mr. Farag is a seasoned biotech and global finance executive, having served as CFO at Aspen Neuroscience and SVP of Finance at Ionis Pharmaceuticals.
The addition of these industry veterans is aimed at guiding BioVie as it advances bezisterim through Phase 2 trials for early Parkinson’s disease and Long COVID, and plans the next steps in its Alzheimer’s disease and ascites programs. Their expertise is considered invaluable for achieving the company's mission.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.